414 related articles for article (PubMed ID: 8501148)
21. Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri.
Scialli AR; Levi AJ
Fertil Steril; 2000 Sep; 74(3):540-6. PubMed ID: 10973652
[TBL] [Abstract][Full Text] [Related]
22. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.
Friedman AJ; Barbieri RL; Doubilet PM; Fine C; Schiff I
Fertil Steril; 1988 Mar; 49(3):404-9. PubMed ID: 2963759
[TBL] [Abstract][Full Text] [Related]
24. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas.
Rein MS; Barbieri RL; Welch W; Gleason RE; Caulfield JP; Friedman AJ
Obstet Gynecol; 1993 Dec; 82(6):901-5. PubMed ID: 8233262
[TBL] [Abstract][Full Text] [Related]
25. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
[TBL] [Abstract][Full Text] [Related]
26. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids.
Thomas EJ
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():18-21. PubMed ID: 8916983
[TBL] [Abstract][Full Text] [Related]
27. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
28. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
Murray SC; Muse KN
Fertil Steril; 1997 Feb; 67(2):390-3. PubMed ID: 9022620
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
30. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
Mitwally MF; Gotlieb L; Casper RF
Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
[TBL] [Abstract][Full Text] [Related]
31. Gonadotropin-releasing hormone agonist use before hysterectomy.
Stovall TG; Summit RL; Washburn SA; Ling FW
Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
[TBL] [Abstract][Full Text] [Related]
32. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
33. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS
Fertil Steril; 1992 Aug; 58(2):413-5. PubMed ID: 1633911
[TBL] [Abstract][Full Text] [Related]
34. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of ipriflavone in preventing adverse effects of leuprolide.
Somekawa Y; Chiguchi M; Ishibashi T; Wakana K; Aso T
J Clin Endocrinol Metab; 2001 Jul; 86(7):3202-6. PubMed ID: 11443189
[TBL] [Abstract][Full Text] [Related]
36. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri.
Scialli AR; Jestila KJ
Fertil Steril; 1995 Aug; 64(2):313-20. PubMed ID: 7615109
[TBL] [Abstract][Full Text] [Related]
37. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
Gram IT; Ursin G; Spicer DV; Pike MC
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1117-20. PubMed ID: 11700258
[TBL] [Abstract][Full Text] [Related]
38. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy.
Barbieri RL
Am J Obstet Gynecol; 1990 Feb; 162(2):593-5. PubMed ID: 2137979
[TBL] [Abstract][Full Text] [Related]
39. [Bone loss induced by GnRHa treatment in women].
Matsuo H
Nihon Rinsho; 2003 Feb; 61(2):314-8. PubMed ID: 12638227
[TBL] [Abstract][Full Text] [Related]
40. "Add-back" therapy for endometriosis in adolescents.
Lubianca JN; Gordon CM; Laufer MR
J Reprod Med; 1998 Mar; 43(3):164-72. PubMed ID: 9564639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
